Magnetic resonance spectroscopy outperforms perfusion in distinguishing between pseudoprogression and disease progression in patients with glioblastoma.
Mohamed Ehab El-AbtahPratik TalatiMelanie FuBenjamin ChunPatrick ClarkAnna PetersAnthony RanasingheJulian HeOtto RapalinoTracy T BatchelorR Gilberto GonzalezWilliam T CurryJorg DietrichElizabeth R GerstnerEva-Maria RataiPublished in: Neuro-oncology advances (2022)
Incorporating enhancing lesion MRSI measures of mI/c-Cr and Lac/Glx into brain tumor imaging protocols can distinguish between PsP and true progression and inform patient management decisions.